These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1299 related items for PubMed ID: 24572997

  • 1. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.
    Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997
    [Abstract] [Full Text] [Related]

  • 2. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
    Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, Jain SS, Michalik DE, Sharma K, Truong DT, Wood JB, Kim KK, Jain S, KIDCARE Multicenter Study Group.
    Lancet Child Adolesc Health; 2021 Dec 17; 5(12):852-861. PubMed ID: 34715057
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
    Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A, RAISE study group investigators.
    Lancet; 2012 Apr 28; 379(9826):1613-20. PubMed ID: 22405251
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
    Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, Miyamae T, Yokota S.
    J Rheumatol; 2012 Apr 28; 39(4):864-7. PubMed ID: 22337241
    [Abstract] [Full Text] [Related]

  • 5. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.
    Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, Atz AM, Li JS, Takahashi M, Baker AL, Colan SD, Mitchell PD, Klein GL, Sundel RP, Pediatric Heart Network Investigators.
    N Engl J Med; 2007 Feb 15; 356(7):663-75. PubMed ID: 17301297
    [Abstract] [Full Text] [Related]

  • 6. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec 15; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 7. Infliximab treatment for refractory Kawasaki syndrome.
    Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, Balfour I, Shen CA, Michel ED, Shulman ST, Melish ME.
    J Pediatr; 2005 May 15; 146(5):662-7. PubMed ID: 15870671
    [Abstract] [Full Text] [Related]

  • 8. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.
    Burns JC, Song Y, Bujold M, Shimizu C, Kanegaye JT, Tremoulet AH, Franco A.
    Clin Exp Immunol; 2013 Dec 15; 174(3):337-44. PubMed ID: 23901839
    [Abstract] [Full Text] [Related]

  • 9. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.
    Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, Baker A, Fulton DR, Sundel RP, Newburger JW.
    J Pediatr; 2011 Apr 15; 158(4):644-649.e1. PubMed ID: 21129756
    [Abstract] [Full Text] [Related]

  • 10. A multicenter, randomized, double-blind, placebo-controlled trial of intravenous ibuprofen 400 and 800 mg every 6 hours in the management of postoperative pain.
    Southworth S, Peters J, Rock A, Pavliv L.
    Clin Ther; 2009 Sep 15; 31(9):1922-35. PubMed ID: 19843482
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
    Fry AM, Goswami D, Nahar K, Sharmin AT, Rahman M, Gubareva L, Azim T, Bresee J, Luby SP, Brooks WA.
    Lancet Infect Dis; 2014 Feb 15; 14(2):109-18. PubMed ID: 24268590
    [Abstract] [Full Text] [Related]

  • 12. [Kawasaki disease: what you need to know].
    Bajolle F, Laux D.
    Arch Pediatr; 2012 Nov 15; 19(11):1264-8. PubMed ID: 22921712
    [Abstract] [Full Text] [Related]

  • 13. Advances in the treatment of Kawasaki disease.
    Dominguez SR, Anderson MS.
    Curr Opin Pediatr; 2013 Feb 15; 25(1):103-9. PubMed ID: 23283289
    [Abstract] [Full Text] [Related]

  • 14. Does abciximab promote coronary artery remodeling in patients with Kawasaki disease?
    McCandless RT, Minich LL, Tani LY, Williams RV.
    Am J Cardiol; 2010 Jun 01; 105(11):1625-8. PubMed ID: 20494673
    [Abstract] [Full Text] [Related]

  • 15. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH.
    PLoS One; 2015 Jun 01; 10(12):e0144603. PubMed ID: 26658843
    [Abstract] [Full Text] [Related]

  • 16. Infliximab as a novel therapy for refractory Kawasaki disease.
    Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS.
    J Rheumatol; 2004 Apr 01; 31(4):808-10. PubMed ID: 15088313
    [Abstract] [Full Text] [Related]

  • 17. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial.
    Sundel RP, Baker AL, Fulton DR, Newburger JW.
    J Pediatr; 2003 Jun 01; 142(6):611-6. PubMed ID: 12838187
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
    Lancet Child Adolesc Health; 2018 Dec 01; 2(12):855-862. PubMed ID: 30337183
    [Abstract] [Full Text] [Related]

  • 19. Aspirin compared with acetaminophen in the treatment of fever and other symptoms of upper respiratory tract infection in adults: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-dose, 6-hour dose-ranging study.
    Bachert C, Chuchalin AG, Eisebitt R, Netayzhenko VZ, Voelker M.
    Clin Ther; 2005 Jul 01; 27(7):993-1003. PubMed ID: 16154478
    [Abstract] [Full Text] [Related]

  • 20. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
    Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF.
    Lancet; 2015 Mar 07; 385(9971):857-66. PubMed ID: 25684586
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.